ProNAi Therapeutics
A clinical-stage oncology company developing DNA interference (DNAi) based cancer therapies.
About
ProNAi Therapeutics is a clinical-stage oncology company focused on developing and commercializing novel cancer therapies. Their proprietary DNA interference (DNAi) technology platform targets specific genes within cancer cells to inhibit proliferation and induce cell death. Their lead candidate, PN Teams look it up for Biotech, Drug Discovery, Clinical Trials.
Frequently asked
What does ProNAi Therapeutics do?
ProNAi Therapeutics is a Biotech company that offers Platform. Teams look it up for Drug Discovery, Clinical Trials, Oncology. It was founded in 2004. Public records show $116M in total funding. Compare it on funding, headcount, reviews and nearby alternatives rather than the marketing line alone.
How much funding has ProNAi Therapeutics raised?
ProNAi Therapeutics has raised a total of $116M in funding. The most recent round on record is Series D.
When was ProNAi Therapeutics founded?
ProNAi Therapeutics was founded in 2004.
What industry does ProNAi Therapeutics operate in?
ProNAi Therapeutics operates in Biotech, Drug Discovery, Clinical Trials, Oncology, Phage Therapy.
What is ProNAi Therapeutics's current status?
ProNAi Therapeutics's current operating status is: Inactive.
Strength of the site’s backlink profile, on Ahrefs’ 0-100 Domain Rating scale. Licensed third-party data, not our opinion.
How well an AI agent can read and use this site: structured data, clean markup, and whether key facts are reachable without running JavaScript. We scan the live site.